MCF Advisors’s PharmaCyte Biotech PMCB Stock Holding History

MCF Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1	Hold	1	–	–	﹤0.01%	1403
2026 Q1	$1	Hold	1	–	–	﹤0.01%	1337
2025 Q4	$1	Buy	+1	New	+$1	﹤0.01%	1133

Other funds holding PMCB

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

MCF Advisors's PMCB Position: Q2 2026 in Review

MCF Advisors held its PharmaCyte Biotech (PMCB) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1403.

MCF Advisors first reported a position in PMCB in Q4 2025 and has held it in 3 quarters since. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

MCF Advisors held 1 share of PharmaCyte Biotech worth $1 as of Q2 2026.
MCF Advisors left its PharmaCyte Biotech share count unchanged in Q2 2026.
PharmaCyte Biotech made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #1403 holding.
MCF Advisors first reported a position in PharmaCyte Biotech in Q4 2025 and has held it in 3 quarters since.
28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.